GLP1R and intestinal obstruction: Our findings support the concept that, when used at standard doses in contemporary RCT populations, GLP-1 receptor agonists as a class do not materially increase intestinal obstruction risk and that liraglutide in particular may exert net favorable effects on motility-related outcomes.